GSK461364 is primarily used in the field of oncology as a potent inhibitor targeting specific kinases involved in cancer cell proliferation. It is particularly effective in inhibiting Polo-like kinase 1 (PLK1), a protein that plays a critical role in cell cycle regulation. By blocking PLK1, GSK461364 disrupts the division of cancer cells, leading to their death. This makes it a promising candidate for the treatment of various cancers, including solid tumors and hematologic malignancies. Research and clinical trials are ongoing to evaluate its efficacy and safety in combination with other anticancer therapies, aiming to enhance treatment outcomes for patients with resistant or advanced cancers.